Publication date: November 2026 Source: Drug Resistance Updates, Volume 89 Author(s): Yeseul Kim, Minju Kim, Haneun Lee, Areum Park, Su Yong Shim, Yura Lee, Kyungjin Lee, Soohyun Lee, Do Young Jin, Jun-Seob Kim, Dongeun Yong, Won-Gon Kim, Choong-Min Ryu, Hyuk Lee, Hwi Won Seo, Jaesung Kwak, Dajeong Kim
Piperidine-derived resensitizers revive aminoglycoside capacity against persister cells of Pseudomonas aeruginosa in vivo. // Drug Resistance Updates. – URL: https://www.sciencedirect.com/science/article/pii/S1368764626001226?dgcid=rss_sd_all
Piperidine-derived resensitizers revive aminoglycoside capacity against persister cells of Pseudomonas aeruginosa in vivo. Drug Resistance Updates. https://www.sciencedirect.com/science/article/pii/S1368764626001226?dgcid=rss_sd_all
“Piperidine-derived resensitizers revive aminoglycoside capacity against persister cells of Pseudomonas aeruginosa in vivo.” Drug Resistance Updates.
@article{article43733,
title = {Piperidine-derived resensitizers revive aminoglycoside capacity against persister cells of Pseudomonas aeruginosa in vivo},
journal = {Drug Resistance Updates},
url = {https://www.sciencedirect.com/science/article/pii/S1368764626001226?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...